NASDAQ:EYPT EyePoint Pharmaceuticals (EYPT) Stock Price, News & Analysis $8.62 +0.61 (+7.62%) (As of 07/3/2024 ET) Add Compare Share Share Today's Range$7.95▼$8.7350-Day Range$8.01▼$19.9452-Week Range$5.67▼$30.99Volume474,594 shsAverage Volume839,869 shsMarket Capitalization$448.93 millionP/E RatioN/ADividend YieldN/APrice Target$33.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get EyePoint Pharmaceuticals alerts: Email Address EyePoint Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside286.1% Upside$33.29 Price TargetShort InterestBearish17.24% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 6 Articles This WeekInsider TradingAcquiring Shares$20.57 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.21) to ($2.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.56 out of 5 starsMedical Sector453rd out of 896 stocksAnalytical Instruments Industry14th out of 27 stocks 4.5 Analyst's Opinion Consensus RatingEyePoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEyePoint Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about EyePoint Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.24% of the outstanding shares of EyePoint Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEyePoint Pharmaceuticals has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in EyePoint Pharmaceuticals has recently increased by 16.02%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEyePoint Pharmaceuticals does not currently pay a dividend.Dividend GrowthEyePoint Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EYPT. Previous Next 1.8 News and Social Media Coverage News SentimentEyePoint Pharmaceuticals has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for EyePoint Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for EYPT on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added EyePoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, EyePoint Pharmaceuticals insiders have bought 13,888.02% more of their company's stock than they have sold. Specifically, they have bought $20,570,223.00 in company stock and sold $147,056.00 in company stock.Percentage Held by InsidersOnly 4.74% of the stock of EyePoint Pharmaceuticals is held by insiders.Percentage Held by Institutions99.41% of the stock of EyePoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about EyePoint Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for EyePoint Pharmaceuticals are expected to decrease in the coming year, from ($2.21) to ($2.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of EyePoint Pharmaceuticals is -4.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of EyePoint Pharmaceuticals is -4.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyePoint Pharmaceuticals has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about EyePoint Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaCatalyst Could Trigger 10,000% Crypto GainsAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. Just take a look: Claim your free seat by clicking here now. About EyePoint Pharmaceuticals Stock (NASDAQ:EYPT)EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Read More EYPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EYPT Stock News HeadlinesJuly 3 at 6:58 AM | americanbankingnews.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Sees Large Growth in Short InterestJune 29, 2024 | americanbankingnews.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives $33.29 Consensus Target Price from AnalystsJuly 5, 2024 | Digital Mavericks Media (Ad)1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income every month.June 28, 2024 | americanbankingnews.comEyePoint Pharmaceuticals' (EYPT) Buy Rating Reaffirmed at Chardan CapitalJune 27, 2024 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT)June 18, 2024 | globenewswire.comEyePoint Pharmaceuticals to Host R&D Day on June 26, 2024June 17, 2024 | globenewswire.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 5, 2024 | globenewswire.comEyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceJuly 5, 2024 | Digital Mavericks Media (Ad)1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income every month.May 29, 2024 | finance.yahoo.comInvesting in EyePoint Pharmaceuticals (NASDAQ:EYPT) a year ago would have delivered you a 91% gainMay 17, 2024 | finance.yahoo.comInsider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)May 16, 2024 | globenewswire.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 13, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals: Maintaining Buy Rating Amidst Progress and TrialsMay 10, 2024 | finance.yahoo.comEyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite ChallengesMay 8, 2024 | investorplace.comEYPT Stock Earnings: EyePoint Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024May 8, 2024 | globenewswire.comEyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate DevelopmentsMay 7, 2024 | markets.businessinsider.comMaintaining Buy Rating on EyePoint Pharmaceuticals Despite P2 Study SetbackMay 7, 2024 | seekingalpha.comEyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead ProgramMay 7, 2024 | markets.businessinsider.comMaintaining Buy Rating on EyePoint Pharmaceuticals: Strong Prospects in wAMD Market Despite NPDR Study SetbackMay 6, 2024 | msn.comEyePoint tumbles 30% premarket on failed Phase 2 studyMay 6, 2024 | seekingalpha.comEyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)May 6, 2024 | finance.yahoo.comWhy Is EyePoint Pharmaceuticals Stock Plummeting On Monday?May 6, 2024 | globenewswire.comEyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic RetinopathyApril 28, 2024 | 247wallst.comThese Biotechs and IPOs Inspire Big Insider BuyingApril 20, 2024 | msn.comVeru, EyePoint Pharmaceuticals, Sintx Technologies among healthcare moversApril 19, 2024 | markets.businessinsider.comBuy Recommendation: EyePoint Pharmaceuticals’ Promising Outlook with EYP-1901 for Diabetic Retinopathy and AMDApril 16, 2024 | globenewswire.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)See More Headlines Receive EYPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/04/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:EYPT CUSIPN/A CIK1314102 Webeyepointpharma.com Phone(617) 926-5000Fax617-926-5050Employees121Year Founded1987Price Target and Rating Average Stock Price Target$33.29 High Stock Price Target$44.00 Low Stock Price Target$28.00 Potential Upside/Downside+286.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,790,000.00 Net Margins-157.77% Pretax Margin-157.60% Return on Equity-49.94% Return on Assets-30.94% Debt Debt-to-Equity RatioN/A Current Ratio5.08 Quick Ratio5.01 Sales & Book Value Annual Sales$46.02 million Price / Sales9.76 Cash FlowN/A Price / Cash FlowN/A Book Value$5.66 per share Price / Book1.52Miscellaneous Outstanding Shares52,080,000Free Float49,615,000Market Cap$448.93 million OptionableOptionable Beta1.58 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Jay S. Duker M.D. (Age 65)President, CEO & Director Comp: $848.5kDr. John B. Landis M.S. (Age 71)Ph.D., Interim Head of R&D and Director Comp: $63.75kMr. Michael Pine (Age 47)Chief Business Officer Comp: $764.85kMr. George O. Elston (Age 59)Executive VP & CFO Comp: $743.86kMr. Michael J. MaciocioSenior Vice President of Manufacturing & OperationsMr. Ron I. Honig Esq.Chief Legal Officer & Company SecretaryMs. Jennifer LeonardChief People Officer & Senior VP of ITMr. David Scott Jones (Age 56)Senior VP & Chief Commercial Officer Comp: $672.08kMs. Isabelle LefebvreChief Regulatory OfficerDr. Marcia Sellos-Moura Ph.D.Senior Vice President of Program LeadershipMore ExecutivesKey CompetitorsFluidigmNASDAQ:FLDMCytek BiosciencesNASDAQ:CTKBStandard BioToolsNASDAQ:LABQuanterixNASDAQ:QTRXPacific Biosciences of CaliforniaNASDAQ:PACBView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 11,639 shares on 5/20/2024Ownership: 0.022%RA Capital Management L.P.Bought 938,591 shares on 5/17/2024Ownership: 1.802%Ikarian Capital LLCBought 375,000 shares on 5/17/2024Ownership: 0.000%California State Teachers Retirement SystemBought 38,878 shares on 5/16/2024Ownership: 0.083%Janus Henderson Group PLCBought 26,856 shares on 5/16/2024Ownership: 0.052%View All Insider TransactionsView All Institutional Transactions EYPT Stock Analysis - Frequently Asked Questions Should I buy or sell EyePoint Pharmaceuticals stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EYPT shares. View EYPT analyst ratings or view top-rated stocks. What is EyePoint Pharmaceuticals' stock price target for 2024? 7 Wall Street analysts have issued 1-year price targets for EyePoint Pharmaceuticals' shares. Their EYPT share price targets range from $28.00 to $44.00. On average, they anticipate the company's stock price to reach $33.29 in the next twelve months. This suggests a possible upside of 286.1% from the stock's current price. View analysts price targets for EYPT or view top-rated stocks among Wall Street analysts. How have EYPT shares performed in 2024? EyePoint Pharmaceuticals' stock was trading at $23.11 at the beginning of the year. Since then, EYPT stock has decreased by 62.7% and is now trading at $8.62. View the best growth stocks for 2024 here. Are investors shorting EyePoint Pharmaceuticals? EyePoint Pharmaceuticals saw a increase in short interest in June. As of June 15th, there was short interest totaling 8,980,000 shares, an increase of 16.0% from the May 31st total of 7,740,000 shares. Based on an average daily volume of 1,100,000 shares, the short-interest ratio is currently 8.2 days. View EyePoint Pharmaceuticals' Short Interest. When is EyePoint Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our EYPT earnings forecast. How were EyePoint Pharmaceuticals' earnings last quarter? EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) announced its earnings results on Wednesday, May, 8th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.21. The company had revenue of $11.68 million for the quarter, compared to analysts' expectations of $12.50 million. EyePoint Pharmaceuticals had a negative trailing twelve-month return on equity of 49.94% and a negative net margin of 157.77%. What ETFs hold EyePoint Pharmaceuticals' stock? ETFs with the largest weight of EyePoint Pharmaceuticals (NASDAQ:EYPT) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). When did EyePoint Pharmaceuticals' stock split? Shares of EyePoint Pharmaceuticals reverse split on Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of EyePoint Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other EyePoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Inovio Pharmaceuticals (INO), Verastem (VSTM), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX). How do I buy shares of EyePoint Pharmaceuticals? Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EYPT) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredThe End of Privacy for Americans… Get Out of Cash Now!Unlock the Secret to Outsmarting Inflation with "The Trump Loophole" That investment? Gold.Golden Crest | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share EyePoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.